The biopharma industry is headed in the right direction when it comes to talking about drug pricing, moving from a discussion about how much money is invested in research and development to a dialog with other stakeholders involved in delivering, paying for and benefitting from new medicines.
Scrip attended panel discussions about drug value, pricing and access, and interviewed drug company executives about the topic during the...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

